Liver disease
Conditions
Interventions
Control group:Placebo
TCM treatment group:Shugan Jianpi Huoxue Formula
Sponsors
Beijing Ditan Hospital Capital Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Meets the diagnostic criteria for high-risk patients with hepatocellular carcinoma among those with compensated hepatitis B cirrhosis.; (2) Male or female aged 18-65 years; (3) Traditional Chinese Medicine (TCM) syndrome differentiation of liver-spleen deficiency with blood stasis obstructing collaterals; (4) Signed informed consent form.
Exclusion criteria
Exclusion criteria: (1) Patients with allergies to Chinese herbal medicine components; (2) Patients without antiviral treatment; (3) Patients previously diagnosed with hepatocellular carcinoma (HCC) or other malignant tumors; (4) Patients co-infected with hepatitis A, E, C or other hepatitis viruses; (5) Patients with autoimmune hepatitis, drug-induced hepatitis, alcoholic liver disease or hereditary metabolic liver diseases; (6) Patients co-infected with HIV or tuberculosis; (7) Patients with severe cardiac/renal complications or other primary diseases; (8) Patients with severe infections, sepsis or hepatorenal syndrome; (9) Pregnant or lactating women; (10) Patients with mental disorders unable to cooperate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HCC incidence; | — |
Secondary
| Measure | Time frame |
|---|---|
| Four Indicators of Liver Fibrosis;Fiberscan;Incidence of Complications;Liver Disease-Related Mortality;Liver function;HBV-DNA load;Hepatitis B Serology Panel;Child-Pugh score;Model for End-stage Liver Disease score;Syndrome Score in Traditional Chinese Medicine; | — |
Countries
China
Contacts
Public ContactXianbo Wang
Beijing Ditan Hospital Capital Medical University
Outcome results
None listed